Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update): a systematic review and economic evaulation

C. Main; L. Ginnelly; S. Griffin; G. Norman; M. Barbieri; L. Mather; D. Stark; S. Palmer; R. Riemsma

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update): a systematic review and economic evaulation

C. Main, L. Ginnelly, S. Griffin, G. Norman, M. Barbieri, L. Mather, D. Stark, S. Palmer, R. Riemsma

Centre for Health Economics

Research output: Working paper

Original language	English
Publication status	Published - 2006

Cite this

@techreport{a96c0786ac044dedb6fee2234ea8ae90,

title = "Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update): a systematic review and economic evaulation",

author = "C. Main and L. Ginnelly and S. Griffin and G. Norman and M. Barbieri and L. Mather and D. Stark and S. Palmer and R. Riemsma",

year = "2006",

language = "English",

type = "WorkingPaper",

}

TY - UNPB

T1 - Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update)

T2 - a systematic review and economic evaulation

AU - Main, C.

AU - Ginnelly, L.

AU - Griffin, S.

AU - Norman, G.

AU - Barbieri, M.

AU - Mather, L.

AU - Stark, D.

AU - Palmer, S.

AU - Riemsma, R.

PY - 2006

Y1 - 2006

M3 - Working paper

BT - Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update)

ER -